Cargando…

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

BACKGROUND & AIMS: Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2 diabetes, but no prospective experimental data exists in NASH. This study determined the effect of a long-acting GLP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armstrong, Matthew J., Hull, Diana, Guo, Kathy, Barton, Darren, Hazlehurst, Jonathan M., Gathercole, Laura L., Nasiri, Maryam, Yu, Jinglei, Gough, Stephen C., Newsome, Philip N., Tomlinson, Jeremy W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713865/ https://www.ncbi.nlm.nih.gov/pubmed/26394161 http://dx.doi.org/10.1016/j.jhep.2015.08.038

Ejemplares similares

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis
por: Armstrong, M J, et al.
Publicado: (2014)

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
por: Armstrong, Matthew J, et al.
Publicado: (2013)

Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
por: Branković, Marija, et al.
Publicado: (2022)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
por: Dowman, J K, et al.
Publicado: (2011)

Lipotoxicity and Decreased Islet Graft Survival
por: Leitão, Cristiane B., et al.
Publicado: (2010)

Non-alcoholic fatty liver disease and lipotoxicity
por: Wasilewska, Natalia, et al.
Publicado: (2021)

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
por: Liu, Cong, et al.
Publicado: (2023)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE(–/–) Mice
por: Liu, Fuqiang, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease and diabetes
por: Hazlehurst, Jonathan M., et al.
Publicado: (2016)

Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice
por: Zhou, Mei, et al.
Publicado: (2017)

Glucagon‐like peptide‐1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway
por: Wu, Lujin, et al.
Publicado: (2018)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
por: Verlinden, Wim, et al.
Publicado: (2020)

Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis
por: Yokomori, Hiroaki, et al.
Publicado: (2020)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis
por: Cannito, Stefania, et al.
Publicado: (2017)

Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RARα-PPARγ-CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice
por: Zhao, Zhuohui, et al.
Publicado: (2022)

Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis
por: Martínez, Laura, et al.
Publicado: (2015)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment
por: Lazure, Patrice, et al.
Publicado: (2022)

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
por: Nestor, John J., et al.
Publicado: (2022)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
por: Barritt, A. Sidney, et al.
Publicado: (2022)

The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice
por: Haczeyni, Fahrettin, et al.
Publicado: (2017)

Sexual dimorphism in inorganic mercury toxicokinetics and the attendant lipotoxic and non-lipotoxic dyslipidemia in the rat
por: Wusu, A.D., et al.
Publicado: (2021)

Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
por: Xue, Huan, et al.
Publicado: (2023)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study
por: Haldar, Debashis, et al.
Publicado: (2019)

Glutamine Modulates Macrophage Lipotoxicity
por: He, Li, et al.
Publicado: (2016)

The Role of Lipotoxicity in Smoke Cardiomyopathy
por: Santos, Priscila P., et al.
Publicado: (2014)

Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018
por: Morgan, Alice, et al.
Publicado: (2021)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis
por: Torres, Sandra, et al.
Publicado: (2021)

Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs
por: Liang, Ruifeng, et al.
Publicado: (2022)

Co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis associated with decreased adiponectin expression in a murine model
por: Takezaki, Daiki, et al.
Publicado: (2023)

Pathogenesis of non-alcoholic fatty liver disease
por: Dowman, J. K., et al.
Publicado: (2010)

How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
por: Geng, Yana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tatm80glva1f8l46bqrnnlc3u3